Abstract
The combination of decreased amyloid β42 (Aβ42) and increased total tau proteins (T-Tau) and phosphorylated tau (P-Tau) in cerebrospinal fluid (CSF) has recently been considered as a biological diagnostic criterion of Alzheimer’s disease (AD). Previous studies showed significant heterogeneity in CSF Aβ42 levels to discriminate AD from non-AD patients. It was also suggested that the CSF amyloid peptide β42/β40 ratio has better diagnostic performance than Aβ42 alone. The objective of the present study was to investigate the potential added value of determining CSF amyloid β40 peptide (Aβ40) for biological diagnosis of AD when CSF Aβ42 levels failed. CSF AD biomarkers were run in 2,171 samples from 1,499 AD and 672 non-AD patients. The following pathologic thresholds were used to define an AD-positive CSF biomarker profile: T-Tau ≥ 400 ng/L, P-Tau181 ≥ 60 ng/L, and Aβ42 ≤ 700 ng/L. CSF Aβ40 was assayed in AD patients with CSF Aβ42 levels above 700 ng/L and non-AD patients with CSF Aβ42 levels below 700 ng/L. CSF Aβ40 levels were higher in AD than non-AD patients. The receiver operator characteristic curves of CSF Aβ40 and the Aβ42/Aβ40 ratio defined AD cut-off values at 12,644 ng/L and 0.06, respectively. In AD patients with non-pathological CSF Aβ42, CSF Aβ40 concentration was able to correct 76.2% of cases when expressed as CSF Aβ42/Aβ40 ratio and 94.7% of cases when used alone. Using CSF Aβ42 and then CSF Aβ40, the percentage of misinterpreted AD patients fell to 1.0%. CSF Aβ40 concentration improved interpretation of Aβ42 level for the diagnosis of AD. CSF Aβ40 alone showed better diagnostic performance than the amyloid peptide Aβ42/Aβ40 ratio. The added value of determining CSF Aβ40 in AD diagnosis now needs confirming in a cohort of definite AD patients and to be completed with novel amyloid cascade biomarkers.
Highlights
According to the revised criteria for Alzheimer’s disease (AD), definite diagnosis is founded on neuropathology as gold standard, when patients meet the clinical and cognitive criteria for AD dementia [1]
The percentage of patients in whom amyloid pathology was misinterpreted fell from 24.2% (525/2,171) using cerebrospinal fluid (CSF) Amyloid β42 (Aβ42) alone to 7.8% (169/2,171) when it was followed by CSF Aβ42/amyloid β40 peptide (Aβ40) ratio, and to 1.7% (37/2,171) when followed by CSF Aβ40 (Figure 2)
We investigated the potential added value of CSF Aβ40 assay to improve the interpretation of Aβ42 level
Summary
According to the revised criteria for Alzheimer’s disease (AD), definite diagnosis is founded on neuropathology as gold standard, when patients meet the clinical and cognitive criteria for AD dementia [1]. Diagnosis of AD onset during the patient’s lifetime is said to be “possible” or “probable.” Amyloid β42 (Aβ42), total Tau (T-Tau), and phosphorylated Tau proteins (P-Tau) assay in cerebrospinal fluid (CSF) is recommended to increase the level of diagnostic certainty for AD in atypical clinical phenotypes, for inclusion of patients in clinical trials and to improve AD diagnosis at the earliest stages of the disease [1,2,3,4,5]. A positive AD CSF biomarker profile was defined as increased CSF Tau and/or P-Tau181 and decreased CSF Aβ42 concentrations [1, 6,7,8]. Rosen et al showed that “normal” CSF Aβ42 levels were observed in AD patients, leading to misinterpretation of the AD CSF biomarker profile in 23.2% of AD patients [10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
